Baxter 2N3374 - Interlink Extension Set 8" 50/Bx, 4 BX/CA

Part Number Baxter 2N3374

SKU Number CIA1087694

Sell Unit BOX

Ships Within 3-5 Days

List Price $317.52

Qty:

Add to Cart

Product Description

Baxter 2N3374 - Interlink Extension Set 8" 50/Bx, 4 BX/CA

Straight -Type Catheter Extension Set, Microbore, INTERLINK Injection Site, 7.6" (19 cm)

Microbore Catheter Extension Sets

Straight-Type Catheter Extension Set Microbore, INTERLINK Injection Site and Male Luer Lock Adapter. Approximate Volume 0.4 mL. Approximate Length 7.6" (19 cm). Non-DEHP. Sterile Package, Nonpyrogenic.

Device Characteristics

What MRI safety information does the labeling contain?	Labeling does not contain MRI Safety Information
Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437):	No
Device labeled as "Not made with natural rubber latex":	Yes
For Single-Use:	Yes
Prescription Use (Rx):	Yes
Over the Counter (OTC):	No
Kit:	No
Combination Product:	No
Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P):	No

Sterilization

Device Packaged as Sterile:	Yes
Requires Sterilization Prior to Use:	No

Pyrogen-free

Pyrogen is any substance that causes a fever. The most commonly thought of pyrogens are bacterial endotoxins and exotoxins, although the host body (human or animal) can also produce pyrogens. The most commonly assayed for pyrogen is lipopolysaccharide, or LPS. It is a component of the bacterial wall of Gram-negative bacteria and is released upon breakdown of the cell wall or bacterial cell lysis. Pyrogen-free products are manufactured in settings that prevent the deposition of bacteria and other agents on the products.

DEHP Free

Infusion Therapy Standards of Practice advise to usee administration sets free of di-ethylhexyl-phthalate (DEHP) to administer lipid-based infusates, such as IVFE or TNA. DEHP is lipophilic and is extracted into the lipid solution with commonly used polyvinyl chloride administration sets and containers. DEHP is considered a toxin, and studies have demonstrated increased DEHP levels in lipid solutions, which is especially a risk with neonatal, pediatric, and long-term home care patients.